All lobbying filings

OTSUKA AMERICA PHARMACEUTICAL, INC.

OTSUKA AMERICA PHARMACEUTICAL, INC. filed a Q2 report for OTSUKA AMERICA PHARMACEUTICAL, INC. on July 18, 2025.

Lobbying for OTSUKA AMERICA PHARMACEUTICAL, INC.

All filings by OTSUKA AMERICA PHARMACEUTICAL, INC. · Everything OTSUKA AMERICA PHARMACEUTICAL, INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Expenses

$1,160,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Taxation/Internal Revenue Code

Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.

Veterans

Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.

Tariff (miscellaneous tariff bills)

Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.

Medicare/Medicaid

Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.

Health Issues

Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.

Budget/Appropriations

Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.

Bills named in this filing 3

H.R. 1
One Big Beautiful Bill Act
S. 832
EPIC Act of 2025
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.